Area of research
Pharmacology · Biological Psychiatry
Research interest
Research interests include Treatment of Major Depression, Tryptophan and brain disorders, Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes, and Schizophrenia research and treatment.
Realising the Convention on the Rights of Persons With Disabilities With Mental Health Advance Directives.
Ketamine for treatment-resistant obsessive-compulsive disorder: Double-blind active-controlled crossover study.
Six weeks open-label oral ketamine for patients with treatment-resistant depression, post-traumatic stress disorder, or obsessive-compulsive disorder.
Systematic Review of the Effect of Psychedelic-Assisted Therapy on Attitudes Toward Death, Life, and Spirituality on Symptoms of Distress, Depression, and/or Anxiety in Patients with Life-Threatening Illness.
Are Baby Boomers hazardous drinkers as they age? An exploratory interRAI study.
Frontal localisation of a theory-based anxiety disorder biomarker - Goal conflict specific rhythmicity.
Linking the Biological Marker Goal-Conflict Specific Rhythmicity (GCSR) and Anxiety Disorder
Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial
Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial.
Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study.
Is lack of goal-conflict-specific rhythmicity a biomarker for treatment resistance in generalised anxiety but not social anxiety or major depression?
Linking the Biological Marker Goal-Conflict Specific Rhythmicity (GCSR) and Anxiety Disorder
Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial
Maintenance ECT treatment in New Zealand: Local and national data.
Randomized Placebo-Controlled Phase 2 Study of Extended-Release Ketamine Tablets (R-107) for Treatment-Resistant Depression – the BEDROC Study
Use of advance directives to promote supported decision-making in mental health care: Implications of international trends for reform in New Zealand.
The short- to medium-term predictive validity of the HoNOS-Secure on violence in a medium-secure forensic psychiatric ward in New Zealand
The Ketamine Side Effect Tool (KSET): A comprehensive measurement-based safety tool for ketamine treatment in psychiatry
Efficacy and Safety of Repeated Subcutaneous Ketamine Injections for Treatment Resistant Depression - The KADS Study: A Randomised, Double-Blind, Comparator-Controlled Trial
Possible mechanisms for treatment heterogeneity in clinical trials of adjunctive N-acetylcysteine for bipolar depression.
Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders.
Right frontal anxiolytic-sensitive EEG 'theta' rhythm in the stop-signal task is a theory-based anxiety disorder biomarker.
Influence of formulation and route of administration on ketamine's safety and tolerability: systematic review.
Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale.
Development of the Ketamine Side Effect Tool (KSET)
Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study.
Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: open label pilot study.
Ketamine and neuroticism: a double-hit hypothesis of internalizing disorders.
Low-risk and high-risk groups matter in suicide risk.
Repeated intranasal ketamine for treatment-resistant depression – the way to go? Results from a pilot randomised controlled trial